Advancing Education on Biosimilars Act of 2021

Summary

Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 12 March 2021

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 12 March 2021

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 12 March 2021

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.